Matt Miksich

Matt Miksich asked about the overall health of the surgical market, including volumes, and Bausch + Lomb's share growth or recovery post-recall. He also followed up on MIEBO's momentum regarding coverage and when XIIdra's investments from late last year/early this year would annualize.

Answer

Chairman and CEO Brent Saunders characterized the cataract surgical market as steady, with a growing patient population and no significant concerns. He confirmed that MIEBO and XIIdra have steady coverage around 70%, which is considered full for the category, and that the investments made for XIIdra in 2025 establish a new baseline, with the investment cycle nearing its end in Q4.

Matt Miksich asked about the overall health and volume trends in the surgical market, particularly for cataract procedures, and sought an update on MIEBO's momentum, its coverage array, and when Bausch + Lomb expects to annualize the investments made in Xiidra.

Answer

Chairman and CEO Brent Saunders indicated that the cataract market is steady with a growing patient population, showing no significant watch-outs. He confirmed that MIEBO and Xiidra coverage is stable at around 70%, which is considered full coverage for the category. Mr. Saunders also stated that the investments in Xiidra were made in 2025, establishing a new baseline, and the company is nearing the end of that investment cycle in Q4.